Mycobacterium smegmatis: The Vanguard of Mycobacterial Research
Open accessThe DOI matches its Crossref record; 191 of the 198 references it cites were found in a registry or an index; 135 of the 193 sources its claims cite were checked for support.
Abstract
155 have since provided previously unattainable insights on these same features in its slow-growing relatives. Notably, tuberculosis (TB) drugs, including the first-line drugs isoniazid and ethambutol, are active against M. smegmatis, but not against E. coli, allowing the identification of their physiological targets. Furthermore, Bedaquiline, the first new TB drug in 40 years, was discovered through an M. smegmatis screen. M. smegmatis has become a model bacterium, not only for M. tuberculosis, but for all other Mycobacterium species and related genera. With a repertoire of bioinformatic and physical resources, including the recently established Mycobacterial Systems Resource, M. smegmatis will continue to accelerate mycobacterial research and advance the field of microbiology.
Overview
CoChat Summary
TL;DR
This review argues that *Mycobacterium smegmatis* mc²155, a fast-growing nonpathogenic mycobacterium isolated in 1990 as a plasmid-transformable mutant, has become the foundational model organism for mycobacterial research, including tuberculosis. It traces the strain's history, the genetic tools and community resources built on it, and the discoveries in conjugation, gene architecture, cell envelope biology, and drug mechanism/target identification that it enabled.
Key findings
- mc²155 arose from a rare transformant of *M. smegmatis* mc²6 that had acquired an efficient plasmid transformation (ept-1) phenotype, routinely yielding up to a million transformants per microgram of plasmid DNA; the mutation was later mapped to *eptC*, encoding a structural-maintenance-of-the-chromosome (SMC) protein.
- Comparative genomics support the model: of ~4,000 *M. tuberculosis* protein-coding genes, >2,800 have orthologs in *M. smegmatis* with >50% amino acid identity; a conservative core of ~1,150 *M. smegmatis* proteins share >50% identity across MTBC, *M. abscessus*, *M. marinum*, *M. avium*, and *M. leprae*; 96% of genes essential in *M. smegmatis* have *M. tuberculosis* orthologs, 90% of which are essential in *M. tuberculosis*.
- The Mycobacterial Systems Resource (MSR) provides 569 precise knockouts of non-essential genes, CRISPRi plasmids targeting 843 genes, and 1,116 Dendra2-tagged fusion constructs; a spatiotemporal analysis of over 700 proteins and a CRISPRi morphological atlas of 263 essential genes both showed that subcellular localization and morphotype cluster with biological function.
- *M. smegmatis* work established distributive conjugal transfer (DCT) as a novel HGT mechanism producing mosaic progeny genomes, implicated ESX-4 in contact-dependent cell-cell communication, revealed abundant leaderless mRNAs (25–30% of mycobacterial mRNAs; 1,285 in *M. tuberculosis*, of which 338 were mis-annotated and 370 unannotated), and underpinned drug work: INH activation by KatG and InhA as its target, EMB's inhibition of EmbA/EmbB arabinosyltransferases, and the initial screen identifying Bedaquiline (diarylquinoline) as an ATP synthase inhibitor.
Methods
- Narrative review synthesizing three decades of published literature on *M. smegmatis* mc²155; no primary experimental data are reported.
- Covers the strain's isolation history, genetic tool development, comparative genomics, community bioinformatic and physical resources (Mycobrowser, BioCyc, MSRdb, Wadsworth Interactive Genomics), and selected discoveries in HGT, gene architecture, secretion, cell envelope biology, and drug discovery.
- The authors also state a position against renaming *M. smegmatis* as *Mycolicibacterium smegmatis*, citing the Tortoli et al. editorial.
Limitations
- Stated by the paper: *M. smegmatis* is more distantly related to slow-growing species and is a poor model for host-pathogen interactions and pathogenesis; *M. bovis* BCG and *M. marinum* are offered as BSL-2 alternatives, though BCG has a complex genealogy with lineage-specific mutations, and in vivo pathogenesis work ultimately requires virulent strains and models such as the *M. tuberculosis*-mouse and *M. marinum*-zebrafish systems.
- Evident from the text: as a narrative review, it is explicitly selective — the authors acknowledge "countless other remarkable contributions" excluded due to space limitations — and it presents no systematic search strategy or quantitative synthesis.
- Evident from the text: the authors are themselves central contributors to much of the work reviewed (mc²155 isolation, MSR, DCT, leaderless mRNA studies), and the anti-renaming stance is an advocacy position rather than a finding.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
79 Valid · 9 Not valid · 26 Not checked · 26 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“While this study established the first, specific platform for validating other potential MmpL3 inhibitors, the technical difficulty involved with creating spheroplasts prompted development of a more high-throughput approach (153).”
What the sources say
- Disputedcites [153] Li W, Stevens CM, Pandya AN, Darzynkiewicz Z, Bhattarai P, Tong W, Gonzalez-Juarrero M, North EJ, Zgurskaya HI, Jackson M. 2019. Direct inhibition of MmpL3 by novel antitubercular compounds. ACS Infect Dis 5:1001–1012. 10.1021/acsinfecdis.9b00048. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Abstract (page not provided) says the M. smegmatis spheroplast assay gave the first direct evidence of TMM buildup following MmpL3 inhibition, not a specific platform for validating potential inhibitors. It explicitly says the assay cannot readily distinguish direct from indirect inhibition; it does support the citing sentence’s point that spheroplast preparation is cumbersome. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, Bedaquiline, the first new TB drug in 40 years, was discovered through an M. smegmatis screen.”
What the sources say
- Supportedcites [147] Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223–227. 10.1126/science.1106753. [DOI] [PubMed] [Google Scholar] source
The opening summary says no tuberculosis-specific drugs had been discovered in 40 years and identifies the diarylquinoline R207910. The Chemistry and in vitro anti-mycobacterial activity section says the discovery strategy tested compounds for inhibition of M. smegmatis growth and led to the diarylquinoline series containing R207910. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RNA-seq analysis demonstrated that donor and recipient cells have specific transcriptional responses to direct contact with the opposite mating type.”
What the sources say
- Partly supportedcites [58] Gray TA, Clark RR, Boucher N, Lapierre P, Smith C, Derbyshire KM. 2016. Intercellular communication and conjugation are mediated by ESX secretion systems in mycobacteria. Science 354:347–350. 10.1126/science.aag0828. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The RNA-profiling passage (indexed under Abstract; page unavailable) describes strain-specific analysis of donor and recipient cells in coculture. The contact-separation passage shows that direct cell-cell contact is required for the recipient’s esx4 transcriptional response, but it does not establish that donor transcriptional responses require direct contact. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The application of RNA-profiling techniques (RNA-seq and Ribo-seq) in M. smegmatis, M. tuberculosis, and M. abscessus (61–64) has emphasized a startling difference in the gene architecture of mycobacteria compared with the textbook model organisms; the presence of leaderless mRNAs (LLmRNA).”
What the sources say
- Supportedcites [61] Cortes T, Schubert OT, Rose G, Arnvig KB, Comas I, Aebersold R, Young DB. 2013. Genome-wide mapping of transcriptional start sites defines an extensive leaderless transcriptome in Mycobacterium tuberculosis. Cell Rep 5:1121–1131. 10.1016/j.celrep.2013.10.031. [DOI] [PMC free article] [PubMed] [Google Scholar] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [62] Miranda-CasoLuengo AA, Staunton PM, Dinan AM, Lohan AJ, Loftus BJ. 2016. Functional characterization of the Mycobacterium abscessus genome coupled with condition specific transcriptomics reveals conserved molecular strategies for host adaptation and persistence. BMC Genomics 17:553. 10.1186/s12864-016-2868-y. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
- Supportedcites [63] Sawyer EB, Phelan JE, Clark TG, Cortes T. 2021. A snapshot of translation in Mycobacterium tuberculosis during exponential growth and nutrient starvation revealed by ribosome profiling. Cell Rep 34:108695. 10.1016/j.celrep.2021.108695. [DOI] [PMC free article] [PubMed] [Google Scholar] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [64] Shell SS, Wang J, Lapierre P, Mir M, Chase MR, Pyle MM, Gawande R, Ahmad R, Sarracino DA, Ioerger TR, Fortune SM, Derbyshire KM, Wade JT, Gray TA. 2015. Leaderless transcripts and small proteins are common features of the mycobacterial translational landscape. PLoS Genet 11:e1005641. 10.1371/journal.pgen.1005641. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The spatiotemporal analysis of over 700 proteins demonstrated that sub-cellular protein localization often correlates with function.”
What the sources say
- Supportedcites [37] Zhu J, Wolf ID, Dulberger CL, Won HI, Kester JC, Judd JA, Wirth SE, Clark RR, Li Y, Luo Y, Gray TA, Wade JT, Derbyshire KM, Fortune SM, Rubin EJ. 2021. Spatiotemporal localization of proteins in mycobacteria. Cell Rep 37:110154. 10.1016/j.celrep.2021.110154. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Discussion says the study characterized the subcellular localization dynamics of over 700 conserved mycobacterial proteins and concludes that localization can be used to infer protein function. The Abstract likewise reports coherent localization patterns among many proteins of known function. The paper’s temporal analysis is a pseudo-temporal reconstruction from static images, consistent with the claim’s broad description. (LLM, conf=0.93)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
64 more claims · 38 with their cited sources checked
Create a free account to see all 140 claims and every source verdict.
- Borderline: one of the tests for a substantial claim is unclear. 1
- It may state two separate claims as one. 49
- Not yet classified. 6
- Probably not a substantial claim. 27
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847 · cited 1×
“tuberculosis (87); most of the SPTKs are membrane proteins, are not SecA2 substrates, and function as mediators of trans-membrane signaling.”
BackgroundGenes required for mycobacterial growth defined by high density mutagenesis
Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03425.x · Cited by 2,544
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
New use of BCG for recombinant vaccines
Stover, C. K., de la Cruz, V. F., Fuerst, T. R., Burlein, J. E., Benson, L. A., Bennett, L. T., Bansal, G. P., Young, J. F., Lee, M. H., Hatfull, G. F., et al. (1991) · Nature · doi:10.1038/351456a0 · Cited by 1,490
Self-citationinhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R. (1994) · Science · doi:10.1126/science.8284673 · Cited by 1,389
Self-citationGenetic requirements for mycobacterial survival during infection
Sassetti, C. M., & Rubin, E. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2134250100 · Cited by 1,354
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299 · cited 1×
“tuberculosis catalase-peroxidase gene, katG, suggesting that susceptibility to INH requires the expression of katG (127).”
BackgroundSnapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., & Jr, W. R. J. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb02040.x · Cited by 1,237
Sreevatsan, S., Pan, X., Stockbauer, K. E., Connell, N. D., Kreiswirth, B. N., Whittam, T. S., & Musser, J. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9869 · Cited by 1,024
Furin, J., Cox, H., & Pai, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30308-3 · Cited by 873
Research works printed but not linked: 2
- Koch R. 1882. Die Aetiologie der Tuberculose. (Nach einem in der physiologischen Gesellschaft zu Berlin am 24.März cr. gehaltenem Vortrage). Berliner Klin Wochenschr 19:221–230. [Google Scholar]
- Minnikin DE. 1982. Lipids: complex lipids, their chemistry, biosynthesis and role, p 95–184. In The biology of mycobacteria. Academic Press, London, UK. [Google Scholar]
Cited by
Items 101–145 of 145
Grimmeisen, M., Wang, X., Weldle, M., Sartory, K., Benkhelifa, S., Zhang, Y., Dao, T., Meyer, J., Gorka, O., Groß, O., et al. (2025) · ChemBioChem · doi:10.1002/cbic.202500390
Isolation and complete genome sequence of a novel Mycobacterium phage MS619
Zhao, Q., Shi, X., Liu, M., & Ji, L. (2025) · Virus Genes · doi:10.1007/s11262-025-02170-2
“Compared with Mycobacterium tuberculosis , M. smegmatis serves as an ideal surrogate for investigating tuberculosis-associated mechanisms because of its faster growth rate, biosafety advantages, and larger genome that retains conserved metabolic and regulatory pathways [17, 18].”
Determining the Functional Roles of Short Open Reading Frames in Mycobacterium Smegmatis
Fox, L. (2023) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/gfht-0e5c
Phase separation of mycobacterial Rho factor is associated with acid stressPreprint
Moreira, S. M., Wade, J. T., & Brown, C. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.28.672908 · Cited by 1
Liang, G.-B., Bai, E., Zhuang, Z., Yang, J., Yu, L., Deng, Y., Duan, Y., & Huang, Y. P. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01856
Shalaby, M. M., Samir, R., Ibrahim, K. A., Elkhamissy, T. R., & Rammadan, M. A. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04361-1 · Cited by 1
“This was possible since M. smegmatis was presented as a surrogate to M. tuberculosis in terms of testing potential drugs and genetic wise [13, 31, 32].”
Madan, M., Bisht, K., Sehrawat, N., & Rao, V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.23.677984
da Silva, I. R., da Silva, Y. C., Ogusku, M. M., et al. (2025) · Natural Product Research · doi:10.1080/14786419.2025.2566906
A Split-Luciferin Assay for Real-Time Measurement of Cytosolic Accumulation in Live MycobacteriaPreprint
Dash, R., Spira, A., Lepori, I., Newkirk, S. E., Bhandari, S., Lucas, N., Chordia, M. D., Siegrist, M. S., & Pires, M. M. (2025) · SSRN Electronic Journal · doi:10.1101/2025.11.02.686125
Takeuchi, H., Mizuno, S., & Matsuo, K. (2025) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2025.10.013
Bashko, G. M., Kornoushenko, Y. V., Tuzikov, A. V., et al. (2025) · Doklady of the National Academy of Sciences of Belarus · doi:10.29235/1561-8323-2025-695-5-367-375
Leukocyte Peptide Complex with Antibacterial and Anti-Inflammatory Effects
Volkova, L. V., Volkov, A. G., Polyudova, T. V., et al. (2025) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2025-70-7-8-28-33
Microfluidic analysis of salt-stress-mediated antibiotic tolerance in Mycobacterium smegmatis
Agrawal, A. V., Kumar, D. U., Mukherjee, R., & Mampallil, D. (2025) · Lab on a Chip · doi:10.1039/d5lc00713e · Cited by 1
Silveiro, C., Mortinho, D., Olivença, F., Mandal, M., Pires, D., Anes, E., & Catalão, M. J. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04548-6 · Cited by 2
“Owing to its rapid growth, genetic homology, and conservation of core metabolic pathways, M. smegmatis ( Msm ) remains a widely used surrogate model for Mtb , particularly in exploratory studies such as this one [62, 63].”
Chauhan, P., Otterdijk, S. V., Commandeur, S., Bald, D., & Bruggeman, F. J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0338563 · Cited by 1
“…of live mycobacteria we chose a non-pathogenic and fast-growing member of the Mycobacterium genus, Mycobacterium smegmatis , which is commonly used as a model bacterium [25] Based on these results, we continued our studies with Vybrant DiD and extended our tests to pathogenic mycobacterial species.”
Rosińska, A., & Wanarska, M. (2025) · Postępy Mikrobiologii - Advancements of Microbiology · doi:10.2478/am-2025-0018
“This appears to be an important discovery because M. smegmatis is a model organism for studying pathogenic bacteria belonging to the genus Mycobacterium (Sparks et al. 2023) .”
Nascimento-Silva, E. A., Matos, A. L. L. D. S., de Souza, T. A., Silva, A. L. E., Abreu, L. S., Merces, M. M., Silva, R. P. A., Filho, U. R. D. S., de Andrade, A. S. A., Tavares, J. F., et al. (2025) · DNA · doi:10.3390/dna6010001
“This phenomenon makes M. smegmatis a valuable tool for identifying compounds, like those in the I339 extract, capable of overcoming the permeability barriers and efflux-mediated resistance that often challenge the treatment of pathogenic mycobacterial infections [42].”
Tennakoon, A., Edirisingha, I., Rutledge, E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.06.698002
“Phage genes that impair M. smegmatis growth can identify conserved processes that are broadly essential across mycobacteria (Sparks et al., 2023).”
Sulyman, A. O., Singh, K., & Naidoo, K. (2026) · Reference series in phytochemistry · doi:10.1007/978-3-031-80866-1_26-1
Quantifying uncertainty of tuberculosis drug susceptibility range from single-microplate test
Postnikov, E. B., & Lavrova, A. I. (2026) · MethodsX · doi:10.1016/j.mex.2026.103797 · Cited by 1
Lam, T., Belculfine, S. J., Gregory, K. N., et al. (2026) · Biotechnology and Bioengineering · doi:10.1002/bit.70343
Self-citationSuryakanta, U., Mishra, S. K., Dhal, A. K., Panigrahi, B., Singh, R. K., & Mandal, D. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c02302
MSMEG_1353 is a critical determinant of metabolic and cell envelope homeostasis in mycobacteriaPreprint
Sodani, M., Desai, S. J., Ansari, A., Shaikh, F. A., Baghel, N. S., & Gupta, P. K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.26.708182
Mycobacterium tuberculosis as a model system
Barnard, E., Elgrail, M. M., Fay, A., Ozakman, Y., & Glickman, M. S. (2026) · Journal of Bacteriology · doi:10.1128/jb.00609-25
Zriba, S., Niroula, N., McDonald, S., Whitecross, D. E., & Chen, J. M. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128545
Sensitivity-Driven Optimization of a Batch Cultivation DAE Model of Mycobacterium smegmatis
Figueroa, C. D., Jélvez, M. G., Bravo, R. T., et al. (2025) · IEEE CHILEAN Conference on Electrical, Electronics Engineering, Information and Communication Technologies (CHILECON) · doi:10.1109/chilecon66915.2025.11476438
A VERSATILE LIBRARY OF TETRACYCLINE-INDUCIBLE AND REPRESSIBLE VECTORS FOR FINE-TUNED GENE EXPRESSIONPreprint
Nair, A. U., James, S., & Jain, V. K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.30.721401
von Soosten, L. C., & Schulz, E. C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.04.722716
Mothupi, R., Matotoka, M. M., Mashabela, G. T., & Masoko, P. (2026) · Microorganisms · doi:10.3390/microorganisms14051133 · Cited by 1
“M. smegmatis is widely used in preliminary drug-screening studies due to its safety, rapid growth, cost-effectiveness, and genetic similarity to M. tuberculosis , eliminating the need for biosafety level 3 facilities [40,41].”
Tran, T. T. Q., Larda, S. T., Nieves, C., et al. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113189
Anand, P., & Akhter, Y. (2026) · Journal of Cellular Biochemistry · doi:10.1002/jcb.70095 · Cited by 1
Intorasoot, S., Doung-Arpai, W., Intorasoot, A., et al. (2026) · Antibiotics · doi:10.3390/antibiotics15060607
“M. smegmatis is widely used for investigating mycobacterial physiology, evaluating drug susceptibility, elucidating mechanisms of action of antimycobacterial agents, and supporting genetic engineering applications [14].”
Godbold, G. D., Sharkey, C. M., Gemler, B. T., Bartling, C. M., Hewitt, F. C., & Gil, J. C. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1818657 · Cited by 1
Ballardo, K. R. O., Campo, K. A.-D., Flores, B. C. A., et al. (2026) · International Journal of Mycobacteriology · doi:10.4103/ijmy.ijmy_8_26
Azhari, M., Isshiki, S., Horinouchi, R., Singgih, M., Arai, M., Garmana, A. N., Hartati, R., Hadisaputri, Y. E., Yuniarti, N., & Julianti, E. (2026) · Marine Drugs · doi:10.3390/md24070236
“The M. smegmatis strain used in this study was M. smegmatis mc 2 155, obtained from the Laboratory of Natural Products for Drug Discovery, Graduate School of Pharmaceutical Sciences, The University of Osaka [12,14].”
Tembiwa, K. E., Truong, A. M., Nguyen, C. T., Gupta, K. R., Rego, E. H., & Boutte, C. C. (2026) · Journal of Bacteriology · doi:10.1128/jb.00269-26
Poroyskiy, S. V., Самотруева, М. А., Цибизова, А. А., Yasenyavskaya, A. L., Генатуллина, Г. Н., & Ренатовна, Б. Г. (2026) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2026-71-3-4-62-69
Rai, R., Chourasia, R., Singh, A. K., et al. (2026) · Next research. · doi:10.1016/j.nexres.2026.102166
Bhausaheb, A. J., Nagarajan, A., Bommidi, J., Koiri, D., Shaikh, J., Choubey, S., Sundaramurthy, V., & Saleem, M. (2026) · iScience · doi:10.1016/j.isci.2026.116745
“38 We first quantified the viability of the bacteria in the experimental conditions through a colony-forming unit (CFU) assay and found it to be ∼ 60% (Figure S4C).”
Rile, E., Diamanti, R., Lundin, D., Sharma, S., Lissner, R., Kuil, C. P., Högbom, M., Bald, D., & Sjöstrand, D. (2026) · FEBS Letters · doi:10.1002/1873-3468.70414
“Infectious species of mycobacteria are diffi-cult and dangerous to work with, and therefore, the nonpathogenic model bacterium Mycobacterium smeg-matis is often used for biochemical studies and protein expression [11,12].”
Bonacorsi, A., Fusco, A., Manessi, D., Filippini, F., Casu, E., Marchetti, M., Palucci, I., Sali, M., Lai, M., Freer, G., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1823245
“…mc 2 155 as host, a rapidly growing, non-pathogenic and prophage-free bacterium, selected for its genetic and physiological similarities to pathogenic mycobacteria (Sparks et al., 2023) and for its ability to produce clean phage lysates without the risk of prophage contaminations (Hatfull, 2023).”
Генатуллина, Г. Н., Цибизова, А. А., Yasenyavskaya, A. L., et al. (2026) · ASTRAKHAN MEDICAL JOURNAL · doi:10.17021/1992-6499-2026-2-68-75
Aguirre, I. C., Priya, M., Garza-García, A., de Carvalho, L. P. S., de Jong, H., & Ropers, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.02.748904
“M. smegmatis is a non-pathogenic species, which has been widely used as a model for M. tuberculosis due to their similar gene content ( ∼ 75% of protein-coding genes), cell envelope composition, and antibiotic susceptibility ( Sparks et al., 2023 ).”
Wu, Q., Zhang, R., Yan, M., Wang, Y., Feng, X., Yang, W., Ding, X.-Y., Sun, Y., Zhan, L., Jin, Q., et al. (2026) · Science Advances · doi:10.1126/sciadv.aee8463
“…were infected with the fast-growing M. smegmatis , a widely recognized surrogate model that shares extensive genetic homologs and comparable cell wall architecture with M. tuberculosis ( 30 ), and then followed by treatment with different PVC- R7-AMP complexes individually or in combination.”
Pratiwi, R. H. (2026) · Journal of Hunan University Natural Sciences · doi:10.55463/issn.1674-2974.53.7.11
Metadata
- Authors
- Sparks, I. L., Derbyshire, K. M., Jacobs, W. R., & Morita, Y. S.
- Affiliations
- University of Massachusetts Amherst (US)
- New York State Department of Health (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- Morita, Yasu S.
- Venue
- Journal of Bacteriology
- Publisher
- American Society for Microbiology
- Published
- 2023-01-26
- Volume
- 205
- Issue
- 1
- Pages
- e0033722-e0033722
- ISSN
- 0021-9193 (ISSN-L)
- 1098-5530
- PMC
- PMC9879119
- OpenAlex
- W4313487963
- Cited by
- 149
- References
- 198
- Citations by year
- 2026: 47 · 2025: 60 · 2024: 29 · 2023: 13
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- doi.org/10.1128/ASMCopyrightv2 (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Bacteriology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | National Institutes of Health (R21 AI144748, R21 AI14760802, R01 GM13927703, R01 AI026170)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- Mycobacterium smegmatis, Mycobacterium tuberculosis, tuberculosis drug discovery, isoniazid, ethambutol, bedaquiline, drug target identification, model organisms
- MeSH terms
- Escherichia coli, Humans, Isoniazid, Mycobacterium tuberculosis, Tuberculosis, Mycobacterium smegmatis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.